Sun Pharma Q1 Profit Beats YoY but Misses Estimates Amid Margin Pressure

📈 Strong Year-on-Year Growth in Net Profit Sun Pharmaceutical Industries reported a consolidated net profit of ₹2,900 Cr in Q1, up from ₹2,300 Cr a year ago — a healthy 26% increase. However, this fell short of market expectations of ₹3,050 Cr. 💰 EBITDA Performance and Margin Dynamics - EBITDA rose to ₹4,420 Cr, slightly ahead of last year’s ₹4,300 Cr and estimates of ₹4,255 Cr. - Despite growth in absolute EBITDA, the margin contracted to 28.9% from 31.1% in Q1 last year, indicating rising cost pressures or product mix shifts. 🔍 Fundamental and Ratio Insights - The dip in EBITDA margin signals potential challenges in pricing or input costs that investors should monitor closely. - Strong net profit growth suggests robust operational execution, supported by a diversified portfolio spanning generics, specialty, and emerging markets. While Sun Pharma’s top-line and profit growth reflect resilience, margin compression introduces caution. Keeping an eye on cost control measures and pipeline developments will be key to assessing sustainable profitability.